Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
GANX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.89 - $5.33
Previous CloseN/A
Volume74.47K
Average Volume (3M)219.48K
Market Cap
$58.36M
Enterprise Value$35.95M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 20, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding26,525,068
10 Day Avg. Volume146,491
30 Day Avg. Volume219,477
Standard Deviation0.21
R-Squared0.00110
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1057.54
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.50Price Target Upside166.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Gain Therapeutics News
PremiumCompany Announcements
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials
PremiumCompany Announcements
Gain Therapeutics Appoints New CEO Amidst Clinical Progress
PremiumCompany Announcements
Gain Therapeutics Advances GT-02287 into Phase 1b Trial
---
Bulls Say, Bears Say
Bulls Say
Drug Discovery PlatformGain is an emerging biotech focused on discovering novel drugs for brain disorders by leveraging its proprietary AI/ML drug discovery platform (Magellan).
Safety And TolerabilityGT-02287 was safe and generally well tolerated across all age groups at all dose levels in both the SAD and MAD portions of the study.
Therapeutic PotentialGT-02287 demonstrated motor and cognition benefits in Parkinson’s disease animal models and positive Phase 1 healthy volunteer data.
Bears Say
Cash ReservesThe company ended the quarter with cash, cash equivalents and marketable securities of $12 mm, compared to $16.8 mm at the end of FY23.
Financial PerformanceThe company reported a 3Q24 net loss of $0.17 per share, moderately narrower than the forecast, driven by lower-than-expected operating expenses.
Risks And CompetitionRisks include clinical and/or commercial failure of GT-02287 in GBA1-PD and/or iPD indications, competition, financing, equity dilution and regulatory setbacks.
---
Ownership Overview
4.90% Insiders
1.14% Mutual Funds
3.61% Other Institutional Investors
89.57% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $0.89 and its highest was $5.33 in the past 12 months.
What is Gain Therapeutics’s market cap?
Gain Therapeutics’s market cap is $58.36M.
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Mar 20, 2025 which is in 41 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.207 by $0.037.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 26,525,068 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.207. Following the earnings report the stock price went up 5.747%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Currently, no hedge funds are holding shares in GANX
---
Gain Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (166.39% Upside)
$6.50 (166.39% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 334.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.72%
12-Months-Change
Fundamentals
Return on Equity
-263.14%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
---
GANX Stock 12 Month Forecast
Average Price Target
$6.50
▲(166.39% Upside)
Technical Analysis
Amicus
―
Ultragenyx Pharmaceutical
―
Blueprint Medicines
―
Oric Pharmaceuticals
―
Pliant Therapeutics
―
Best Analysts Covering GANX
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
+4.93%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +4.93% per trade.
---